These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30414937)

  • 1. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer.
    Vallette FM; Olivier C; Lézot F; Oliver L; Cochonneau D; Lalier L; Cartron PF; Heymann D
    Biochem Pharmacol; 2019 Apr; 162():169-176. PubMed ID: 30414937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy.
    Swayden M; Chhouri H; Anouar Y; Grumolato L
    Cells; 2020 Dec; 9(12):. PubMed ID: 33291749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer.
    Cabanos HF; Hata AN
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological agents targeting drug-tolerant persister cells in cancer.
    Chen YC; Gowda K; Amin S; Schell TD; Sharma AK; Robertson GP
    Pharmacol Res; 2024 May; 203():107163. PubMed ID: 38569982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance in cancer therapy: role of the microenvironment.
    Galmarini CM; Galmarini FC
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Cancer Cell Dormancy.
    Recasens A; Munoz L
    Trends Pharmacol Sci; 2019 Feb; 40(2):128-141. PubMed ID: 30612715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria.
    Kester JC; Fortune SM
    Crit Rev Biochem Mol Biol; 2014; 49(2):91-101. PubMed ID: 24328927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
    Kim BH; Yi EH; Ye SK
    Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PerSort Facilitates Characterization and Elimination of Persister Subpopulation in Mycobacteria.
    Srinivas V; Arrieta-Ortiz ML; Kaur A; Peterson EJR; Baliga NS
    mSystems; 2020 Dec; 5(6):. PubMed ID: 33262242
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug-Tolerant Persister Cells in Cancer Therapy Resistance.
    Dhanyamraju PK; Schell TD; Amin S; Robertson GP
    Cancer Res; 2022 Jul; 82(14):2503-2514. PubMed ID: 35584245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes and their role in tumorigenesis and anticancer drug resistance.
    Milman N; Ginini L; Gil Z
    Drug Resist Updat; 2019 Jul; 45():1-12. PubMed ID: 31369918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease in cancer therapy--Small things make all the difference.
    Blatter S; Rottenberg S
    Drug Resist Updat; 2015; 21-22():1-10. PubMed ID: 26307504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.
    Ramirez M; Rajaram S; Steininger RJ; Osipchuk D; Roth MA; Morinishi LS; Evans L; Ji W; Hsu CH; Thurley K; Wei S; Zhou A; Koduru PR; Posner BA; Wu LF; Altschuler SJ
    Nat Commun; 2016 Feb; 7():10690. PubMed ID: 26891683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epigenome and the many facets of cancer drug tolerance.
    Moore PC; Henderson KW; Classon M
    Adv Cancer Res; 2023; 158():1-39. PubMed ID: 36990531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida albicans biofilms produce antifungal-tolerant persister cells.
    LaFleur MD; Kumamoto CA; Lewis K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3839-46. PubMed ID: 16923951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cancer cell bioenergetics in dormancy and drug resistance.
    Tau S; Miller TW
    Cancer Metastasis Rev; 2023 Mar; 42(1):87-98. PubMed ID: 36696004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer chemoresistance; biochemical and molecular aspects: a brief overview.
    Kachalaki S; Ebrahimi M; Mohamed Khosroshahi L; Mohammadinejad S; Baradaran B
    Eur J Pharm Sci; 2016 Jun; 89():20-30. PubMed ID: 27094906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical oncology: New targets for nanomedicine.
    Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
    Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.